• Noortje Thielen, Bronno van der Holt, Gregor E G Verhoef, Rianne A H M Ammerlaan, Pieter Sonneveld, Jeroen J W M Janssen, Wendy Deenik, J H Frederik Falkenburg, Marie José Kersten, Harm A M Sinnige, Martin Schipperus, Anton Schattenberg, Rien van Marwijk Kooy, Willem M Smit, Isabel W T Chu, Peter J M Valk, Gert J Ossenkoppele, and Jan J Cornelissen.
• Department of Hematology, VU University Medical Center, De Boelelaan 1117, Amsterdam, the Netherlands. n.thielen@vumc.nl
• Ann. Hematol. 2013 Aug 1; 92 (8): 1049-56.

AbstractDespite the revolutionary change in the prognosis of chronic myeloid leukemia (CML) patients with the introduction of imatinib, patients with resistant disease still pose a considerable problem. In this multicenter, randomized phase III trial, we investigate whether the combination of high-dose imatinib and intermediate-dose cytarabine compared to high-dose imatinib alone, improves the rate of major molecular response (MMR) in newly diagnosed CML patients. This study was closed prematurely because of declining inclusion due to the introduction of second generation tyrosine kinase inhibitors and only one third of the initially required patients were accrued. One hundred nine patients aged 18-65 years were randomly assigned to either imatinib 800 mg (n = 55) or to imatinib 800 mg in combination with two successive cycles of cytarabine 200 mg/m(2) for 7 days (n = 54). After a median follow-up of 41 months, 67 % of patients were still on protocol treatment. The MMR rate at 12 months was 56 % in the imatinib arm and 48 % in the combination arm (p = 0.39). Progression-free survival was 96 % after 1 year and 89 % after 4 years. Four-year overall survival was 97 %. Adverse events grades 3 and 4 were more common in the combination arm. The addition of intermediate-dose of cytarabine to imatinib did not improve the MMR rate at 12 months. However, the underpowering of the study precludes any definitive conclusions. This trial is registered at www.trialregister.nl (NTR674).

45 keywords...

hide…